Gafurbhai M. Bilakhia
Gafurbhai M. Bilakhia | |
|---|---|
| Born | Gafurbhai M. Bilakhia |
| Nationality | Indian |
| Occupation(s) | Industrialist, Philanthropist |
| Known for | Founder of Bilakhia Group, Meril Life Sciences, Maa Foundation |
| Awards | Padma Shri (2020) |
Gafurbhai M. Bilakhia is an Indian industrialist and philanthropist, known for his contributions to trade, industry, and social welfare. He is the founder of the Bilakhia Group, which operates in healthcare, education, and technology. In 2020, he was awarded the Padma Shri, for his contributions to industry.[1][2]
Career
Bilakhia started his career in Vapi, Gujarat, managing a warehouse before identifying opportunities in the printing inks industry. He later founded Micro Inks, which became one of the largest ink manufacturers globally. Over time, the Bilakhia Group expanded into medical technology, education, and philanthropy.[3][4]
Recognition
In 2020, Bilakhia received the Padma Shri for his contributions to trade and industry.[5][6]
Legacy
Known as Bapuji, Bilakhia's sons currently manage the Bilakhia Group, ensuring the continuation of his vision and leadership.[7]
See also
References
- ^ "Padma Awards 2020: Check out the winners". Deccan Herald. 10 November 2021. Retrieved 27 July 2025.
- ^ "Full list of 2020 Padma awardees". The Hindu. 26 January 2020. ISSN 0971-751X. Retrieved 16 March 2025.
- ^ Bharat, E. T. V. (28 January 2020). "Padma Shri Gafurbhai M. Bilakhia speaks about his journey". ETV Bharat News. Retrieved 15 March 2025.
- ^ "Four trustees inducted in Vidyapith". Ahmedabad Mirror. Retrieved 15 March 2025.
- ^ "85 વર્ષની ઉંમર સુધીમાં ગફૂર બિલખીયાએ જે સેવાકાર્ય કર્યું, તેના માટે પદ્મ પુરસ્કાર પણ ઓછો પડે..." Zee News Gujarati. Retrieved 15 March 2025.
- ^ Rajput, Kajal (21 February 2023). "Gujarat Minister Kanubhai Desai inaugurated Dr Agarwals first super specialty eye hospital in Vapi". medicaldialogues.in. Retrieved 15 March 2025.
- ^ "Four new trustees appointed at Gujarat Vidyapith". The Indian Express. 2 January 2023. Retrieved 15 March 2025.